个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Phase I study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody MIL62 in Chinese patients with relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma

| 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Shi, Y-K.[1] * ; Song, Y.[2] ; Qin, Y.[1] ; Zhou, K.[2] ; Gao, Y.[3] ; Wang, M.[4] ; Wang, P.[2] ; Yin, Q.[2] ; Zhao, F.[1] ; Ma, G.[3] ; Li, F.[5] ;
机构： [1]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China [2]Hematology Department, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China [3]Hematology Department, The Fourth Hospital of Hebei Medical University (Hebei Cancer Hospital), Shijiazhuang, China [4]Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University (Hebei Cancer Hospital), Shijiazhuang, China [5]Beijing Mabworks Biotech Co. Ltd., Beijing Mabworks Biotech Co. Ltd., Beijing, China
出处：
DOI： 10.1016/j.annonc.2020.08.013
ISSN：
基金：
Beijing Mab-works Biotech Co. Ltd.
语种：
外文
被引次数：
WOS：
中科院分区：
出版当年[2020]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2020]版：
Q1 ONCOLOGY
最新[2024]版：
Q1 ONCOLOGY

影响因子： 最新[2024版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者：
第一作者机构： [1]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
推荐引用方式(GB/T 7714)：
Shi Y-K.,Song Y.,Qin Y.,et al.Phase I study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody MIL62 in Chinese patients with relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma[J].ANNALS OF ONCOLOGY.2020,31:S652-S652.doi:10.1016/j.annonc.2020.08.013.
APA：
Shi, Y-K.,Song, Y.,Qin, Y.,Zhou, K.,Gao, Y....&Li, F..(2020).Phase I study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody MIL62 in Chinese patients with relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma.ANNALS OF ONCOLOGY,31,
MLA：
Shi, Y-K.,et al."Phase I study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody MIL62 in Chinese patients with relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma".ANNALS OF ONCOLOGY 31.(2020):S652-S652

资源点击量：42326 今日访问量：0 总访问量：1365 更新日期：2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号